OBJECTIVES: To describe treatment patterns and cost in patients with PSO (psoriasis) receiving biologic therapies (BT). METHODS: A retrospective cohort of medication claims data from IMS Brogan Private (Canadian national) and Public (Ontario and Quebec) Drug Plan databases was analysed.  Biologic-naïve PSO patients >18 years of age were selected between 01/01/2007 and 03/30/2011 and followed for 24 months to understand lines of therapy, retention on BT, and annual therapy costs. Target biologics included adalimumab, etanercept, infliximab and ustekinumab. RESULTS: